EPLR 2/2019 (Vol. 3)

Editorial

Sabrina Röttger-Wirtz

Seite 55 - 57

The Coherency of Regulatory Requirements for Homeopathic Medicinal Products in the EU and the EAEU open-access

Gunther Herr, Alexander Natz, Robbert van Haselen

Seite 58 - 72

Off-Label Use Reimbursement: A Review of the Status Quo in the Context of the Recent Novartis/AIFA Case

Peter von Czettritz, Alexander Meier

Seite 73 - 81

Continued Uncertainty for the GDPR and Clinical Trials

William Long, Francesca Blythe

Seite 82 - 85

A Spoonful of Sugar Makes the Medicine go Down: Pay for Delay and Market Definition in the Servier Judgment

Flip van der Kraan, Wolf Sauter

Seite 86 - 94

What Innovative Pharmaceutical Research is Protected under the SPC-Regime? A Discussion of the ECJ's Decision in the Abraxis Case

Otto Swens, Carly van der Beek

Seite 95 - 100

Jurisdiction

Seite 101 - 103

New EU Pharmaceutical Law and Policy

Seite 104